Has Tobias Else, MD received payments from drug or device companies?

Yes. Drug and device makers reported $31,036 in general payments to Tobias Else, MD across 25 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tobias Else, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tobias Else, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tobias Else, MD

Endocrinology, Diabetes & Metabolism · Ann Arbor, MINPI 1518120161

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $22,780 of the $31,036 with a category attached, or 73.4%. 5 manufacturers reported payments, led by Merck at 43.9% of the total. Reporting peaked in 2020 at $8,481 and has fallen 50.1% since, to $4,236 in 2025.

$31,036in general payments, 2019–2025

Across 25 payments — averaging $1241.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$14K
Corcept Therapeutics$10K
HRA Pharma RARE Diseases$5K
Progenics Pharmaceuticals, Inc.$2K
E.r. Squibb & Sons, L.L.C.$116

$3,500,298in research payments, 2019–2025

Across 61 payments — averaging $57,382 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$3.4M
Strongbridge US Inc.$50K
Xeris Pharmaceuticals, Inc.$830
Corcept Therapeutics$40

What the payments were for

Consulting fees$22,78073%
Speaking & faculty fees$5,72518%
Travel & lodging$1,8316%
Food & beverage$7002%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	5	$13,630
Corcept Therapeutics	15	$9,815
HRA Pharma RARE Diseases	2	$5,400
Progenics Pharmaceuticals, Inc.	2	$2,075
E.r. Squibb & Sons, L.L.C.	1	$116

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Korlym$9,503
Lysodren$5,400
AZEDRA$2,075
COBENFY$116

How this compares

$31,036 in reported general payments places this provider in the 85th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan →

Medicare billing

Part B allowed, 2024

$12,182

Medicare patients

Services billed

155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
WeliregBelzutifan	22	$429,434
Testosterone	12	$2,424
Hydrocortisone	23	$817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
MerckWelireg	$13,630	$429,43422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

Other endocrinology, diabetes & metabolism in Ann Arbor

Richard AuchusAnn Arbor$250K
Elif OralAnn Arbor$81K
Kenneth FeingoldAnn Arbor$43K
William HermanAnn Arbor$42K
Amy RothbergAnn Arbor$29K
Joanna Spencer-SegalAnn Arbor$24K
Gary HammerAnn Arbor$15K
Arash SoleimanpourAnn Arbor$14K
Tae Hwa ChunAnn Arbor$7K
Lowell SchmeltzFarmington Hills$1.3M

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →